My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Garden Silk Mills announces demise of director
Jan 23,2017

Garden Silk Mills announced that Arunchandra N. Jariwala, an Independent Director of the Company passed away on 21 January 2017.

Powered by Capital Market - Live News

NRB Bearings announces change in directorate
Jan 23,2017

NRB Bearings announced that the Board by Circular Resolution dated 23 January 2017 has appointed:

1. Rustom Desai as an Additional Director on the Board of the Company in the category of a Non- Executive and Independent Director w.e.f. 23 January 2017 upto the date of the next Annual General Meeting;

2. Satish C Rangani as an Additional Director on the Board of the Company in the category of a Whole -Time Director, designated Executive and Company Secretary w.e.f. 24 January 2017 upto the date of the next Annual General Meeting;

Rustom Desai will also be a member of the Nomination & Remuneration Committee and Risk & Business Strategy Committee.

Powered by Capital Market - Live News

Mukta Arts bring New Excelsior under its brand Mukta A2 Cinemas
Jan 23,2017

Mukta Arts has bought the prestigious South Mumbai Cinema New Excelsior under its Mukta A2 Cinemas brand through its newly formed wholly owned subsidiary, Mukta A2 Cinemas.

The renovation of the theatre is complete and its is expected to open very soon. This brings the screen count of Mukta A2 Cinemas at 50.

Powered by Capital Market - Live News

Suven Life Sciences secures product patent form Australia
Jan 23,2017

Suven Life Sciences has been granted one (1) product patent from Australia (2013382944) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and the Patent is valid through 2033.

The granted claims of the patents are from the mechanism of action include the class of selective 5HT4 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders likeAlzheimers disease, Attention deficient hyperactivity disorder (ADHD), Huntingtons disease, Major Depressive disorder (MDD), Parkinson and Schizophrenia.

With these new patents, Suven has a total of twenty five (25) granted patents from Australia. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

Powered by Capital Market - Live News

Industrial & Prudential Investment Company to announce Q3 results
Jan 23,2017

Industrial & Prudential Investment Company announced that a Meeting of the Board of Directors of the Company is scheduled to be held on 09 February 2017, inter alia, to consider and approve the Standalone Unaudited Financial Results of the Company for the third quarter ended 31 December 2016.

Powered by Capital Market - Live News

Board of Omax Autos to consider Q3 and 9M results
Jan 23,2017

Omax Autos announced that the next Board Meeting of the Company is scheduled to be held on 30 January 2017 inter alia, to consider; the Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2016.

Powered by Capital Market - Live News

HEG to consider Q3 and 9M results
Jan 23,2017

HEG announced that a meeting of the Board of Directors of the Company is scheduled to be held on 08 February 2017, inter alia, to consider the unaudited financial results of the Company for the quarter & nine months period ended 31 December 2016.

Powered by Capital Market - Live News

JSW Energy drops after poor Q3 outcome
Jan 23,2017

The result was announced during market hours today, 23 January 2017.

Meanwhile, the S&P BSE Sensex was up 90.66 points or 0.34% at 27,125.16.

On the BSE, 10.32 lakh shares were traded on the counter so far as against the average daily volumes of 5.52 lakh shares in the past one quarter. The stock had hit a high of Rs 62 and a low of Rs 58.90 so far during the day.

The stock had hit a 52-week high of Rs 86.20 on 30 June 2016 and a 52-week low of Rs 53.50 on 9 November 2016. The stock had outperformed the market over the past one month till 20 January 2017, advancing 3.72% compared with the Sensexs 2.76% rise. The scrip had, however, underperformed the market over the past one quarter, declining 14.55% as against the Sensexs 3.89% fall.

The large-cap company has equity capital of Rs 1640.05 crore. Face value per share is Rs 10.

The decline in the companys turnover in Q3 December 2016 was primarily on account of lower generation coupled with lower tariff. The companys net generation declined 23.26% to 4,644 units in Q3 December 2016 over Q3 December 2015, primarily on account of poor power demand across all thermal plants besides shutdown of one unit of 300 megawatts (MW) at Ratnagiri due to turbine vibrations.

JSW Energys consolidated earnings before interest, taxation, depreciation and amortization (EBITDA) declined 39.69% to Rs 708 crore in Q3 December 2016 over Q3 December 2015. Lower EBITDA was due to lower generation, lower average tariff realisation and higher variable cost per unit.

On the future business outlook, JSW Energy said that while margins are expected to be under pressure in the short term due to subdued demand for power coupled with the firming up of international coal prices, the impending pickup in economic activity coupled with lower interest rate regime is expected to provide opportunities to optimise cost and secure power purchase agreements in the longer term.

The company believes that given the Government of Indias firm resolve to push the economy on the fast track, issues related to low per capita consumption of power and non-availability of 24x7 power to almost 70% of the population will necessarily have to be addressed, leading to a huge surge in the demand for power in the medium term.

JSW Energy is a part of JSW Group and is a integrated power company.

Powered by Capital Market - Live News

Outcome of board meeting of JSW Energy
Jan 23,2017

JSW Energy announced that the Board of Directors of the Company at its meeting held on 23 January 2017 transacted the following -

Noted resignation of Pramod Menon as Director-Finance and CFO with effect from 31 January 2017.

Appointment of Jyoti Kumar as CFO and KMP of the Company with effect from 01 February 2017.

Appointment of Monica Chopra as Company Secretary and KMP with effect from 23 January 2017.

Powered by Capital Market - Live News

Ramco Systems partners with Malaysias Matrix Group
Jan 23,2017

Multi-disciplinary manufacturer and supplier of Food & Beverage flavours, Matrix Sdn. Bhd. announced that it will implement Ramco Systems Enterprise Resource Planning solution, to automate its Production, Sales, Administration and HR functions.

Global enterprise software provider Ramco will roll out its integrated ERP solution across Matrixs three legal entities, which manufacture food ingredients, oleo chemicals and bleaching earth, respectively.

Ramcos mobile-friendly system will enable Matrix to integrate Process Production, Sales and Distribution, Inventory, Procurement and Sub-contracting with Finance and Accounting in addition to automating HR &Payroll. Compliant with the Malaysian statutory requirements, Ramco ERP will also integrate with Matrixs existing bar code and dosing systems to automate and increase efficiency and productivity of employees.

Powered by Capital Market - Live News

Lupin receives final approval for Paroxetin Extended Release Tablets
Jan 23,2017

Lupin has received final approval for its Paroxetin Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg from the United StatesFood and Drug Administration (FDA) to market a generic version of Apotex Technologies, Incs Paxil CRn++ Tablets, 12.5 mg, 25 mg and 37.5 mg. Lupin shall commence promoting the product shortly.

Lupins Paroxetin Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg are the AB rated generic equivalents of Apotex Technologies, Incs Paxil CRn++ Tablets, 12.5 mg, 25 mg and 37.5 mg. It is indicated for the treatment of major depressive disorder, panic disorder, social anxiety disorder and premenstrual dysphoric disorder.

Paxil CRn++ Tablets had US sales of USD 127.7 million (IMS MAT September 2016).

Powered by Capital Market - Live News

UCO Bank to announce Q3 results
Jan 23,2017

UCO Bank announced that meeting of the Board of Directors of the Bank will be held on 31 January 2017, inter alia, to consider the unaudited Financial Results of the Bank for the 3rd quarter ended on 31 December 2016 (Q3).

Powered by Capital Market - Live News

Board of Labh Construction to consider Q3 results
Jan 23,2017

Labh Construction announced that the meeting of the Board of Directors will be held on 14 February 2017, inter alia, to consider and approve following business(s):

- Adoption of Unaudited Quarterly Financial Results of the Company for the 3rd quarter ended on 31 December 2016.

Powered by Capital Market - Live News

NIIT allots 30000 equity shares
Jan 23,2017

NIIT announced that the Share Allotment Committee of the Board of Directors of the Company has allotted 30,000 (Thirty Thousand) Equity Shares of Rs. 2/- each to the employee of the Company in accordance with the terms of ESOP-2005.

Powered by Capital Market - Live News

Gati to announce Q3 and 9M results
Jan 23,2017

Gati announced that a meeting of the Board of Directors of the Company will be held on 07 February 2017, inter alia, to consider and approve the unaudited financial results (Standalone & Consolidated) of the Company for the quarter and nine months ended 31 December 2016 (Q3).

Powered by Capital Market - Live News